Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Safety Study of Ataluren in Nonsense Mutation Dystrophinopathy
NCT01247207Phase 3Terminated
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Nov 2010
- Primary completion
- Feb 2026
- Countries
- 2
01
Overview
A Phase 3 trial of ataluren in Duchenne muscular dystrophy (DMD), sponsored by PTC Therapeutics, Inc.. Started Nov 2010; status: terminated.
02
Drugs
ataluren
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT01247207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01247207.